header logo image


Page 1,577«..1020..1,5761,5771,5781,579..1,5901,600..»

Embryonic stem cell therapy in China (www.esctherapy.com)

August 14th, 2011 8:32 am

Since 2002, ESC therapy has treated over 10000 patients with degenerative diseases, injury and cancer, now it has move on to help people to delay ageing as disease usually comes from weaken and aged cells.

View post:
Embryonic stem cell therapy in China (www.esctherapy.com)

Read More...

Dr. Chein discusses Autologous Stem Cell Therapy – Palm Springs

August 12th, 2011 2:31 am

Over the decades, multiple procedures have been developed to achieve a more youthful and vibrant look such as using fillers to smooth out the deep wrinkles and lines on the face.

More:
Dr. Chein discusses Autologous Stem Cell Therapy - Palm Springs

Read More...

Stroke Victim Improved With Stem Cell Therapy. More at http://www.stemcellfusion.com

August 11th, 2011 3:50 pm

Read more:
Stroke Victim Improved With Stem Cell Therapy. More at http://www.stemcellfusion.com

Read More...

Lou Gehrig’s Disease: Stem Cell Therapy Pre-Clinical Studies

August 10th, 2011 2:44 am

(Part 5 of 8) Martin Marsala MD spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010.

Original post:
Lou Gehrig's Disease: Stem Cell Therapy Pre-Clinical Studies

Read More...

Post Stem Cell Therapy Video for Cerebral Palsy

August 9th, 2011 1:47 pm

Stem Cell Therapy for Cerebral Palsy done at Neurogen Brain and Spine Institute Pvt. Ltd. India.

Original post:
Post Stem Cell Therapy Video for Cerebral Palsy

Read More...

A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview)

August 7th, 2011 4:09 pm

In 1989 when scientists discovered the defective gene that causes cystic fibrosis, a serious hereditary disorder that primarily strikes children of European descent, it seemed as though a long-hoped-for cure might soon follow. After all, tests in many laboratories showed that providing normal copies of the gene should enable patients to make healthy copies of the protein specified by the gene. If successful, that feat would go a long way toward restoring health in the tens of thousands of people around the world who suffered from cystic fibrosis and typically died in their late 20s. (Half of all patients now live to their late 30s or beyond.) The question was whether researchers would be able to reliably insert the correct gene into the proper tissues in patients’ bodies to rid them of the illness forever.

That task proved harder than anyone had believed. Although scientists successfully engineered viruses to ferry copies of the correct gene into patients’ cells, the viruses did not do the job well. By the late 1990s additional unexpected complications made it increasingly obvious that another approach to addressing the fundamental problem in cystic fibrosis would need to be found.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Read More...

International Stem Cell Corporation Chairman Ken Aldrich Interviewed by Ellis Martin

August 7th, 2011 4:09 pm
"The Ellis Martin Report features interviews with exciting, potentially undervalued small and mid-cap publicly traded companies, showcased to an audience of potential retail investors during market hours throughout the United States."

Ellis Martin with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)
Listen to full interview here: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share or you can read a Transcript of the conversation here: http://www.ellismartinreport.com/node/148
(Scroll down to view this week's Radio Schedule for ISCO.)
“International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich.
International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists.
The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline Cell Tech’s products are distributed in the United States and Europe.”


Monday, August 1st at 1:00pm

WVNJ-NY/NJ - AM1160      

Tuesday, August 2nd at 10:00am
KCEO - AM1000    
San Diego/Orange County/LA Beach Cities

Tuesday, August 2nd at 9:30am and Friday, August 5th at 3:30pm
WSBR-AM - 740 FM 95.5  
Boca Raton, West Palm Beach, Ft. Lauderdale, Miami

Mondays and Wednesdays at 1:00pm
WBNM-AM 1120
Boston and New England through: WESO AM 970 and WCRN AM 830
Ellis Martin Report
http://www.ellismartinreport.com  
International Stem Cell Corporation
http://www.intlstemcell.com  
Contact: martinreports@gmail.com  
International Stem Cell Corporation is a paid sponsor of The Ellis Martin Report

Click here to listen to the entire interview: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share

Read More...

A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview)

August 7th, 2011 4:06 pm

In 1989 when scientists discovered the defective gene that causes cystic fibrosis, a serious hereditary disorder that primarily strikes children of European descent, it seemed as though a long-hoped-for cure might soon follow. After all, tests in many laboratories showed that providing normal copies of the gene should enable patients to make healthy copies of the protein specified by the gene. If successful, that feat would go a long way toward restoring health in the tens of thousands of people around the world who suffered from cystic fibrosis and typically died in their late 20s. (Half of all patients now live to their late 30s or beyond.) The question was whether researchers would be able to reliably insert the correct gene into the proper tissues in patients’ bodies to rid them of the illness forever.

That task proved harder than anyone had believed. Although scientists successfully engineered viruses to ferry copies of the correct gene into patients’ cells, the viruses did not do the job well. By the late 1990s additional unexpected complications made it increasingly obvious that another approach to addressing the fundamental problem in cystic fibrosis would need to be found.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Read More...

International Stem Cell Corporation Chairman Ken Aldrich Interviewed by Ellis Martin

August 7th, 2011 4:06 pm
"The Ellis Martin Report features interviews with exciting, potentially undervalued small and mid-cap publicly traded companies, showcased to an audience of potential retail investors during market hours throughout the United States."

Ellis Martin with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)
Listen to full interview here: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share or you can read a Transcript of the conversation here: http://www.ellismartinreport.com/node/148
(Scroll down to view this week's Radio Schedule for ISCO.)
“International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich.
International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists.
The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline Cell Tech’s products are distributed in the United States and Europe.”


Monday, August 1st at 1:00pm

WVNJ-NY/NJ - AM1160      

Tuesday, August 2nd at 10:00am
KCEO - AM1000    
San Diego/Orange County/LA Beach Cities

Tuesday, August 2nd at 9:30am and Friday, August 5th at 3:30pm
WSBR-AM - 740 FM 95.5  
Boca Raton, West Palm Beach, Ft. Lauderdale, Miami

Mondays and Wednesdays at 1:00pm
WBNM-AM 1120
Boston and New England through: WESO AM 970 and WCRN AM 830
Ellis Martin Report
http://www.ellismartinreport.com  
International Stem Cell Corporation
http://www.intlstemcell.com  
Contact: martinreports@gmail.com  
International Stem Cell Corporation is a paid sponsor of The Ellis Martin Report

Click here to listen to the entire interview: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share

Read More...

Stem Cell Therapy for Cerebral Palsy – Holly Catalano

August 2nd, 2011 6:31 am

Holly is now able to crawl and sit up on her own just 7 weeks after her second treatment for cerebral palsy at the Stem Cell Institute in Panama City, Panama.

Go here to read the rest:
Stem Cell Therapy for Cerebral Palsy - Holly Catalano

Read More...

Poor Diet May Make COPD Worse, Study Finds

July 31st, 2011 4:06 pm

(HealthDay News) -- Certain vitamin deficiencies may lead to decreased lung function in people with chronic obstructive pulmonary disorder (COPD), which includes emphysema and chronic bronchitis, says a new study.

For the study, 20 COPD patients (13 women, seven men) completed a questionnaire to assess their dietary intake of vitamins A, C, D, E and selenium, all of which contain cell-protecting antioxidants. A diet low in antioxidants -- as compared to national dietary intake requirements -- was common among the patients.

The percentages of deficiencies were: 25 percent (selenium), 45 percent (vitamin C), 90 percent (vitamin E), 55 percent (vitamin A), and 70 percent (vitamin D).

The researchers then measured the maximum amount of air the patients could exhale with force. All the patients with a selenium-deficient diet had decreased lung function. Among patients deficient in vitamins C, A, and D, only men had decreased lung function. Read more...

Ayurtox for Body Detoxification

Read More...

Clinical trial costs

July 31st, 2011 4:06 pm
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com
Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

July 31st, 2011 4:06 pm
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

Poor Diet May Make COPD Worse, Study Finds

July 31st, 2011 4:03 pm

(HealthDay News) -- Certain vitamin deficiencies may lead to decreased lung function in people with chronic obstructive pulmonary disorder (COPD), which includes emphysema and chronic bronchitis, says a new study.

For the study, 20 COPD patients (13 women, seven men) completed a questionnaire to assess their dietary intake of vitamins A, C, D, E and selenium, all of which contain cell-protecting antioxidants. A diet low in antioxidants -- as compared to national dietary intake requirements -- was common among the patients.

The percentages of deficiencies were: 25 percent (selenium), 45 percent (vitamin C), 90 percent (vitamin E), 55 percent (vitamin A), and 70 percent (vitamin D).

The researchers then measured the maximum amount of air the patients could exhale with force. All the patients with a selenium-deficient diet had decreased lung function. Among patients deficient in vitamins C, A, and D, only men had decreased lung function. Read more...

Ayurtox for Body Detoxification

Read More...

Clinical trial costs

July 31st, 2011 4:03 pm
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com
Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

July 31st, 2011 4:03 pm
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

Stem Cell Therapy–Hillcrest Animal Hospital

July 31st, 2011 1:49 am

Hillcrest Animal Hospital, Bartlett, TN.....now doing in house stem cell therapy to relieve clinical signs of arthritis in dogs To learn more about stem cell therapy and how its helping animals across the United States, visit http://www.medivet-america.com

More:
Stem Cell Therapy--Hillcrest Animal Hospital

Read More...

Stem Cell Therapy – Knee Surgery Alternative

July 28th, 2011 6:21 pm

Helen shares her experiences with Dr. Matos and the Jacksonville Anti-Aging Institute. Helen suffered from severe leg and knee pain, had problems walking, and was unable to bend her knees up to her chest.

Read more from the original source:
Stem Cell Therapy - Knee Surgery Alternative

Read More...

The New World of Medicine: Stem Cell Therapy

July 26th, 2011 7:25 pm

In this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?

Original post:
The New World of Medicine: Stem Cell Therapy

Read More...

Adult Stem Cell Therapy Clinical Advances – Dr. Jorge Paz in San Diego, CA March 2011

July 26th, 2011 3:16 pm

Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined. Dr.

Original post:
Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011

Read More...

Page 1,577«..1020..1,5761,5771,5781,579..1,5901,600..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick